Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

Background Addition of trastuzumab to first-line chemotherapy improves overall survival in
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …

Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate.
We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

The success of immune checkpoint blockade in patients with a wide variety of malignancies
has changed the treatment paradigm in oncology. However, combination therapies with …

Tumor-associated macrophages (TAMs) are important tumor-promoting cells in the breast
tumor microenvironment. Preclinically TAMs stimulate breast tumor progression, including …

Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …

The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …